BioCryst Pharmaceuticals (BCRX)
(Delayed Data from NSDQ)
$4.45 USD
-0.03 (-0.67%)
Updated May 3, 2024 04:00 PM ET
After-Market: $4.43 -0.02 (-0.45%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.45 USD
-0.03 (-0.67%)
Updated May 3, 2024 04:00 PM ET
After-Market: $4.43 -0.02 (-0.45%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Zacks News
Conatus Pharma (CNAT) Incurs Wider-than-Expected Loss in Q4
by Zacks Equity Research
Conatus Pharmaceuticals Inc. (CNAT) reported fourth-quarter 2016 loss of 35 cents per share, wider than both the Zacks Consensus Estimate of a loss of 32 cents and the year-ago figure of 30 cents.
AstraZeneca's Cancer Drug Lynparza Positive in Phase III
by Zacks Equity Research
AstraZeneca plc (AZN) announced positive results from phase III SOLO-2 study which support the potential benefit of marketed drug Lynparza (olaparib) as a maintenance therapy in relapsed ovarian cancer.
Arena Pharmaceuticals (ARNA) Posts Q4 Earnings, Revenues Up
by Zacks Equity Research
Arena Pharmaceuticals, Inc. (ARNA) reported earnings of 16 cents per share in the fourth quarter of 2016, as against the year-ago loss of 13 cents and the Zacks Consensus Estimate of a loss of 9 cents.
BioCryst Pharmaceuticals (BCRX) Shares March Higher, Can It Continue?
by Zacks Equity Research
BioCryst Pharmaceuticals, Inc. (BCRX) has been on the move lately as the stock has risen by 46.8% in the past four weeks, and it is currently trading well above its 20-Day SMA
After Valeant, Here are 5 Drug Stocks Bill Ackman Should Buy Instead
by Arpita Dutt
With Bill Ackman finally deciding to exit Valeant (VRX), here is a look at 5 Zacks Rank #1 and #2 drug stocks that the billionaire investor could consider buying.
Adamis (ADMP) Shows Strength: Stock Gains 6.7% in Session
by Zacks Equity Research
Adamis Pharmaceuticals Corporation (ADMP) moved big last session, as its shares rose over 6% on the day
Is the Options Market Predicting a Spike in BioCryst Pharmaceuticals (BCRX) Stock?
by Zacks Equity Research
Investors in BioCryst Pharmaceuticals, Inc. (BCRX) need to pay close attention to the stock based on moves in the options market lately.
Is the Options Market Predicting a Spike in BioCryst Pharmaceuticals (BCRX) Stock?
by Zacks Equity Research
Investors in shares of BioCryst Pharmaceuticals, Inc. (BCRX) need to pay close attention to the stock based on moves in the options market lately.
Can The Uptrend Continue for BioCryst Pharmaceuticals (BCRX)?
by Zacks Equity Research
Investors certainly have to be happy with BioCryst Pharmaceuticals, Inc. (BCRX) and its short term performance.
3 Biotechs Looking Good this Earnings Season
by Zacks Equity Research
A number of biotech companies are seeing improvements in their financial results.